Feasibility, Accuracy, and Reproducibility of Virtual Reality Visual Field Testing in Patients With Glaucoma

Condition(s) studied

Investigational drug(s) / intervention(s)

Virtual Reality Visual Field (VR-VF): Both devices administer a standard visual field test. The Humphrey is the gold standard desk top model and the VR-VF is a virtual reality headset designed to deliver visual field testing

Study summary

The goal of this clinical trial is to evaluate the feasibility of using virtual reality based visual field testing to monitor glaucoma in a clinical setting. This will be done through comparison of a virtual reality (VR) based device to the current gold standard Ziess Humphrey Field Analyzer (HFA). The main questions the study aims to answer are:

* Can both devices produce similar results in terms of detecting visual field defects and progression?
* Does the stage (early, moderate, advanced) of glaucoma impact results between the two devices?

Participants will perform both a standard and a VR based visual field test at each visit, for a total of 5 visits.

Eligibility

Primary outcome measure(s)

• Visual field point-wise threshold values — Measured during each visual field test on visits 1 through 5 (throughout study completion, average 2 months)
  Both the VR visual field and HFA produce threshold light sensitivity values measured in decibels (db) at the same locations in space (e.g., 24-2 protocol with stimuli 6 degrees apart at locations up to 30 degrees from central fixation)
• Global indices of visual field loss — Measured during each visual field test on visits 1 through 5 (throughout study completion, average 2 months)
  Mean deviation (MD) and pattern standard deviation (PSD) are measurements of global field loss produced by both devices.
• Reliability Indices — Measured during each visual field test on visits 1 through 5 (throughout study completion, average 2 months)
  Fixation losses, false positives, false negatives are recorded during each visual field test and reflect the reliability of the given test.

Trial sites (1)

More Nova Scotia Health Authority trials in Canada